SpyGlass Pharma Inc SGP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $24.62
- Day Range
- $24.63–25.79
- 52-Week Range
- $17.06–32.44
- Bid/Ask
- $21.10 / $30.00
- Shares Outstanding
- 33.45M
- Market Cap
- $833.52M
- Volume/Avg
- 68,252 / 109,780
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 65
- Website
- https://www.spyglasspharma.com
Valuation
|
Metric
|
SGP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.59 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SGP
|
|---|---|
Quick Ratio | 24.89 |
Current Ratio | 25.06 |
Interest Coverage | — |
Quick Ratio
SGP
Profitability
|
Metric
|
SGP
|
|---|---|
Return on Assets (Normalized) | −27.09% |
Return on Equity (Normalized) | −68.06% |
Return on Invested Capital (Normalized) | −74.13% |
Return on Assets
SGP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<?l%!< | LOCK|#^P#! | $129B | |||
| Moderna Inc
MRNA
| LOCK|!^Pf^k | LOCK|M# | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|R%!$QJ | LOCK|D%Z?W | $77B | |||
| argenx SE ADR
ARGX
| LOCK|TJf<xy# | LOCK|jQ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@!!YSJ% | LOCK|Mc | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!GCG#fy | LOCK|SQ!l? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|h^W!$dy< | LOCK|rpl$K | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Y$%^yx | LOCK|?q | $24B | |||
| Incyte Corp
INCY
| LOCK|<@n#<!% | LOCK|#Xs | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|ZlplNP | LOCK|#%M | $14B |
United States